HER2-low Hormone Receptor Positive Breast Cancer Clinical Trials in Shanghai, Shanghai Municipality

A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients